UNSPSC 51314305: Carbinoxamine/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314305 Carbinoxamine/pseudoephedrine is a Commodity code that shows minimal alignment with recent state and local procurement activity. The three most recent opportunities tagged to this code actually solicited naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — none of which match the code's nominal scope of a specific antihistamine-decongestant combination. The code's abstract definition and the work state and local governments are actually buying under this tag diverge sharply, suggesting either broad category misapplication or administrative mislabeling in how jurisdictions are classifying their pharmaceutical procurements.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, through competitive bidding for quarterly deliveries to the Seminole County Community Health Building. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026, with a March 26, 2026, deadline to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, including Oregon, with awarded vendors effective July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler arrangements. The code shows no meaningful concentration among issuing bodies or geographic region — activity reflects isolated state health agency and county procurement actions with no repeat buyers evident. Because the code's label and recent solicitations show substantial mismatch, this code warrants caution; the pharmaceutical products actually being bought fall outside carbinoxamine/pseudoephedrine specification, and opportunities may not reliably surface under this code going forward.